The healthcare company builder Puretech registers one success and one failure, both underlining the need for robust mid-stage data.
Celgene’s registrational Transcend NHL-001 study will be a big story at Ash, but the early focus falls on what has not been presented.
Smaller projects dominate the list, but this doesn’t make them any less important for November’s hopefuls.
The amyloid-beta project is to be filed for Alzheimer’s, and Biogen’s market cap regains the $15bn it lost in March.
Roche is set to lose its crown as the largest oncology player to the newly merged Bristol-Myers Squelgene, while Astrazeneca is forecast to streak up the rankings.
One of the company’s Xeljanz follow-ons is slowly emerging from stealth mode in atopic dermatitis.
Hiking the price of a drug before generics appear is a long-enshrined practice, a situation that applies to most of the products singled out by Icer.
Non-US big biopharma stocks led the way in the third quarter, suggesting that those looking for investment gains would do best to search further afield.
An analysis of stock market movers during the period of this year’s Esmo congress gives biotech watchers little cause for happiness.